for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Evoke Pharma Inc

EVOK.OQ

Latest Trade

0.92USD

Change

-0.03(-3.26%)

Volume

37,292

Today's Range

0.85

 - 

0.95

52 Week Range

0.50

 - 

3.32

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.95
Open
0.95
Volume
37,292
3M AVG Volume
17.15
Today's High
0.95
Today's Low
0.85
52 Week High
3.32
52 Week Low
0.50
Shares Out (MIL)
24.11
Market Cap (MIL)
22.93
Forward P/E
-2.72
Dividend (Yield %)
--

Latest Developments

More

Evoke Pharma Completed Manufacturing Commercial Scale Batches Of Product Candidate Gimoti

Evoke Pharma Reports Q2 Loss Per Share $0.09

Evoke Pharma Requests Type A FDA Meeting To Plan For Resubmission Of Gimoti NDA

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Evoke Pharma Inc

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

Industry

Biotechnology & Drugs

Contact Info

420 Stevens Ave Ste 370

+1.858.3451494

https://evokepharma.com/

Executive Leadership

Cam L. Garner

Chairman and Co Founder

David A. Gonyer

CEO, Founder, Director

Matthew J D'Onofrio

Executive Vice President, Chief Business Officer Treasurer, Secretary ,

Marilyn R. Carlson

Chief Medical Officer

Todd C. Brady

Director

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.150

2017

-0.820

2018

-0.460

2019(E)

-0.350
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.61
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-125.73
Return on Equity (TTM)
-103.24

Latest News

BRIEF-Evoke Pharma Granted Gender Specific Patent For Gimoti In Mexico

* EVOKE GRANTED GENDER SPECIFIC PATENT FOR GIMOTI™ IN MEXICO Source text for Eikon: Further company coverage:

BRIEF-Evoke Announces Agreement With Mallinckrodt To Amend Milestone Payments

* EVOKE ANNOUNCES AGREEMENT WITH MALLINCKRODT TO AMEND MILESTONE PAYMENTS

BRIEF-Evoke Pharma Q4 Loss Per Share $0.02

* EVOKE PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

BRIEF-‍Mr Green Acquires Evoke Gaming Including Redbet​

* PURCHASE PRICE OF EUR 7 MILLION IN CASH; AN ADDITIONAL PURCHASE PRICE OF EUR 1.5 MILLION MAY BE PAYABLE IF CERTAIN CONDITIONS ARE MET

BRIEF-Evoke Pharma reports Q3 loss per share $0.34

* Evoke Pharma reports third quarter 2017 results and highlights

BRIEF-Evoke Pharma signs commercial agreement with Thermo Fisher Scientific

* Announced selection of Patheon division of Thermo Fisher Scientific as commercial manufacturing partner for Gimoti

BRIEF-Evoke Pharma reports positive topline results from comparative exposure pharmacokinetic study for gimoti

* Evoke Pharma announces positive topline results from comparative exposure pharmacokinetic study for gimoti™

BRIEF-Evoke pharma completes dosing for Gimoti™comparative exposure Pharmacokinetic study

* Evoke pharma completes dosing for Gimoti™ comparative exposure Pharmacokinetic study

BRIEF-Evoke Pharma reports Q2 loss per share $0.11

* Evoke Pharma reports second quarter 2017 results and highlights

BRIEF-Evoke pharma inc initiates comparative exposure Pharmacokinetic Study for Gimoti

* Evoke Pharma Inc - initiation of its comparative exposure Pharmacokinetic trial for Gimoti

BRIEF-Evoke Pharma enters agreement with Rho to submit NDA for Gimoti

* Evoke Pharma enters agreement with Rho to submit NDA for Gimoti

BRIEF-Evoke Pharma Q1 loss per share $0.37

* Q1 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Evoke Pharma presents Gimoti efficacy and safety data from phase 3 trial

* Evoke Pharma presents Gimoti efficacy and safety data from phase 3 trial as late breaker at digestive disease week 2017

BRIEF-Evoke Pharma announces collaboration with Spaulding Clinical Research

* Evoke Pharma Inc- announces collaboration with Spaulding Clinical Research for Gimoti comparative exposure pharmacokinetic trial

BRIEF-Meeting with FDA confirms acceptability of Evoke's proposed trial for Gimoti NDA

* Positive type A meeting with FDA confirms acceptability of Evoke Pharma’S proposed comparative exposure PK trial for Gimoti NDA

BRIEF-Evoke Pharma Q4 loss per share $0.12

* Evoke pharma reports fourth quarter and full year 2016 results

BRIEF-Evoke Pharma announces pricing of public offering

* Evoke Pharma announces pricing of public offering of common stock

BRIEF-FDA exempts Evoke from requirement for human factor validation study

* FDA exempts Evoke from requirement for human factor validation study

BRIEF-Evoke Pharma reports Q3 loss per share of $0.29

* Q3 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up